title: Redox-active metals, oxidative stress, and Alzheimer's disease pathology.
abstract: Considerable evidence is mounting that dyshomeostasis of the redox-active biometals, Cu and Fe, and oxidative stress contribute to the neuropathology of Alzheimer's disease (AD). Present data suggest that metals can interact directly with Abeta peptide, the principal component of beta-amyloid that is one of the primary lesions in AD. The binding of metals to Abeta modulates several physiochemical properties of Abeta that are thought to be central to the pathogenicity of the peptide. First, we and others have shown that metals can promote the in vitro aggregation into tinctorial Abeta amyloid. Studies have confirmed that insoluble amyloid plaques in postmortem AD brain are abnormally enriched in Cu, Fe, and Zn. Conversely, metal chelators dissolve these proteinaceous deposits from postmortem AD brain tissue and attenuate cerebral Abeta amyloid burden in APP transgenic mouse models of AD. Second, we have demonstrated that redox-active Cu(II) and, to a lesser extent, Fe(III) are reduced in the presence of Abeta with concomitant production of reactive oxygen species (ROS), hydrogen peroxide (H(2)O(2)) and hydroxyl radical (OH*). These Abeta/metal redox reactions, which are silenced by redox-inert Zn(II), but exacerbated by biological reducing agents, may lead directly to the widespread oxidation damages observed in AD brains. Moreover, studies have also shown that H(2)O(2) mediates Abeta cellular toxicity and increases the production of both Abeta and amyloid precursor protein (APP). Third, the 5' untranslated region (5'UTR) of APP mRNA has a functional iron-response element (IRE), which is consistent with biochemical evidence that APP is a redox-active metalloprotein. Hence, the redox interactions between Abeta, APP, and metals may be at the heart of a pathological positive feedback system wherein Abeta amyloidosis and oxidative stress promote each other. The emergence of redox-active metals as key players in AD pathogenesis strongly argues that amyloid-specific metal-complexing agents and antioxidants be investigated as possible disease-modifying agents for treating this horrible disease.
authors.affiliation: Laboratory for Oxidation Biology, Genetics and Aging Research Unit, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts 02129, USA. huangx@helix.mgh.harvard.edu
authors.forename: Xudong
authors.initials: X
authors.lastname: Huang
authors.forename: Robert D
authors.initials: RD
authors.lastname: Moir
authors.forename: Rudolph E
authors.initials: RE
authors.lastname: Tanzi
authors.forename: Ashley I
authors.initials: AI
authors.lastname: Bush
authors.forename: Jack T
authors.initials: JT
authors.lastname: Rogers
mesh_terms: D000544:Alzheimer Disease / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology*; D000682:Amyloid / Q000378:metabolism; D000818:Animals; D000975:Antioxidants / Q000627:therapeutic use; D002614:Chelating Agents / Q000627:therapeutic use; D006801:Humans; D008670:Metals / Q000378:metabolism*; D010084:Oxidation-Reduction; D018384:Oxidative Stress
chemical_list: D000682:Amyloid; D000975:Antioxidants; D002614:Chelating Agents; D008670:Metals